WallStSmart

DexCom Inc (DXCM)vsInspira Technologies Oxy BHN Ltd (IINN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 1666993% more annual revenue ($4.82B vs $289,000). DXCM leads profitability with a 19.3% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 72/100 (B).

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.7Profit: 8.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.67

IINN

Avoid

15

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DXCMUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$656.95

Current Price

$75.14

$581.81 discount

UndervaluedFair: $656.95Overvalued

Intrinsic value data unavailable for IINN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 9.0/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

EPS GrowthGrowth
92.2%10/10

Earnings expanding 92.2% YoY

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

IINN0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

IINN4 concerns · Avg: 3.8/10
Price/BookValuation
12.1x4/10

Trading at 12.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$18.91M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.

Bull Case : IINN

IINN has a balanced fundamental profile.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Bear Case : IINN

The primary concerns for IINN are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

DXCM profiles as a mature stock while IINN is a value play — different risk/reward profiles.

IINN carries more volatility with a beta of 2.16 — expect wider price swings.

DXCM is growing revenue faster at 15.0% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 15/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Inspira Technologies Oxy BHN Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Inspira Technologies Oxy BHN Ltd., a specialty medical device company, is engaged in the research, development, manufacture and commercialization of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory insufficiency. The company is headquartered in Ra'annana, Israel.

Want to dig deeper into these stocks?